Merger Rules Shouldn't Stifle Drug Development: Vestager
The European Commission may be missing the chance to review companies' acquisition of potentially important innovative drugs because of the way its merger notification rules currently work, Competition Commissioner Margrethe Vestager...To view the full article, register now.
Already a subscriber? Click here to view full article